Catalogue detailing the available datasets and associated variables in the consortium

WP1 will systematically identify all available biomedical AF screening study sources comprehensively characterize them for the research proposed in the consortium Table 11 Data in three outcome trials powered for strokeSE 160000 participants in the community STROKESTOP studies and primary care Danish LOOP SAFER are complemented by five clinical studies with different depth of additional phenotyping 200000 individuals Step 1 AFFECTEU will establish a data inventory by comprehensively characterizing the available data sources for accessibility size of dataset ie availability of risk factorshealth determinants number and type of blood samples spectrum of data collected selfreported data electronic health records clinical lifestyle imaging epigenetic and omics information type and duration of followup Important information will be the type and characteristics of screening the device applied the accuracy of AF diagnosis completeness of rhythm monitoring and additional details related to the screening process itself including barriers to screening Patientreported outcome measures POEMs PatientOriented Evidence that Matters quality of life and potential harms by screening and the inconveniences of the screening procedure itself will be captured A minimum of patientcentred outcomes data comprising patientreported clinicianreported and administrative metrics as well as outcome metrics for POEMs outcomes relevant for providerspayersregulators will be suggested for harmonization All partners will provide an overview of their data collection and variable manuals that will be harmonized and compiled in a central data base Interactive retrieval tools WP 6 will support the exploitation of variables through the established catalogue to get summary information and understand similarities and differences between the diverse studiesStep 2 A working platform for efficient data retrieval and exchange will be established technically supported by WP6